Jeuveau vs Dysport: Onset, Diffusion, Units, and Patient Fit

What you are deciding between

Jeuveau (prabotulinumtoxinA-xvfs) and Dysport (abobotulinumtoxinA) are two of the five FDA-approved botulinum toxin type A neuromodulators available for aesthetic use in the United States. Both relax targeted facial muscles to smooth dynamic wrinkles. Both are injectable, in-office procedures with minimal downtime.

They are not interchangeable — the units are measured on different scales, the molecular formulations differ, and the tissue behavior after injection is not the same. The choice between them is not "which is better" but which profile matches your anatomy, your goals, and your injector's experience.

The basics at a glance

Mechanism: same family, different molecules

Both products are botulinum toxin type A. Both work by blocking the presynaptic release of acetylcholine at the neuromuscular junction — the signal that tells a muscle to contract. When that signal is interrupted, the muscle relaxes and the overlying skin smooths.

The differences that matter clinically come from the manufacturing process and the surrounding protein complex, not from the core neurotoxin. Jeuveau uses a proprietary purification process developed by Daewoong Pharmaceuticals. Dysport uses Ipsen's manufacturing process. Both include non-toxin accessory proteins as part of a 900 kDa complex, but the specific protein composition and ratios differ.

The FDA makes this point explicitly: potency units are specific to each preparation and its assay method. Units of one product cannot be compared to or converted into units of any other botulinum toxin product. The clinical "approximately 2.5–3:1" Dysport-to-Botox ratio, and the approximately 1:1 Jeuveau-to-Botox ratio, are consensus clinical conventions — not label conversions. Providers should follow the labeled dose for each product and adjust based on individual patient response.

Onset and duration

Dysport: faster onset

Dysport is widely reported to show initial results within 2–3 days of injection, with full effect visible by about 2 weeks. This faster onset is one of the most consistently cited advantages in clinical practice and has been noted in comparative studies against onabotulinumtoxinA.

The faster onset is thought to relate to Dysport's wider molecular dispersion, which may allow the toxin to reach more nerve terminals more quickly in the treatment zone.

Jeuveau: comparable to Botox

Jeuveau's onset is typically reported at 3–5 days, with full results at about 2 weeks — broadly similar to Botox Cosmetic. Some providers report that it can appear slightly faster than Botox in certain patients, but the Phase III trials did not demonstrate a statistically significant onset difference compared to placebo controls evaluated at the standard time points.

Duration: roughly equivalent

Both products last approximately 3–4 months for most patients, consistent with the duration reported across all botulinum toxin type A neuromodulators (excluding Daxxify, which uses a peptide-stabilized formulation lasting 6+ months). Individual duration depends on metabolism, muscle strength, dose, treatment area, and treatment history.

Tissue spread: the practical difference

This is where the two products diverge most meaningfully.

Dysport diffuses more widely from each injection point. This is an advantage when treating larger surface areas — horizontal forehead lines, for example — where a softer, more blended effect is desirable. It is a disadvantage when precise placement matters, such as near the eyebrow margin where unintended spread could cause ptosis (drooping eyelid).

Jeuveau is more locally contained. Its spread profile is closer to Botox, making it better suited for precision work: the glabellar complex, crow's feet, a subtle brow lift, or any area where you want the effect to stay where it was placed.

Neither spread profile is inherently better. The right choice depends on the area being treated and the result you want.

Dosing and unit conversion

The unit systems are different, and this is where patients and providers sometimes get confused — especially around pricing.

• Jeuveau is dosed similarly to Botox on a per-unit basis. The FDA-labeled dose for glabellar lines is 20 Units — the same labeled dose as Botox Cosmetic (20 Units).
• Dysport requires roughly 2.5–3 times more units to achieve a similar clinical effect. The FDA-labeled dose for glabellar lines is 50 Units — divided into 5 injection sites of 10 Units each.

This does not mean Dysport is "stronger" or "weaker." It means the unit of measurement is smaller. When comparing prices per unit between products, you must account for the different dose per area. A clinic charging $4/unit for Dysport and $12/unit for Jeuveau may end up at a similar total cost per treatment area.

Cost considerations

Per-treatment costs vary widely by geography, provider, and practice. As of 2026:

• Jeuveau is often positioned at a slightly lower per-unit price point than Botox, and may be comparable to or slightly less expensive than Dysport on a per-treatment basis.
• Dysport pricing varies because the higher unit count per treatment area can confuse per-unit comparisons.
• Both are typically less expensive per treatment session than Daxxify, which commands a premium for its longer duration.

The real cost question is cost-per-month of effect. If Dysport and Jeuveau both last 3–4 months and have similar per-session costs, the annualized cost is roughly the same. If one product consistently lasts longer for your anatomy, it becomes the better value regardless of per-unit price.

Who is each product best for?

Dysport may be the better choice if:

• You are treating a larger area (forehead) and want a softer, more blended result
• Faster onset matters to you (upcoming event, preference for quick feedback)
• Your injector is experienced with Dysport's diffusion pattern and knows how to dose accordingly
• You have previously used Botox or Jeuveau and felt the result was too localized or "patchy"

Jeuveau may be the better choice if:

• You want precise, targeted treatment — glabellar lines, crow's feet, a subtle brow adjustment
• You prefer a product designed exclusively for cosmetic use (Jeuveau has no therapeutic indications)
• You are switching from Botox and want a similar placement and spread profile
• Your injector has more experience with the 1:1 unit dosing convention

Neither is the right choice if:

• You want the longest possible duration between treatments — Daxxify (6+ months) is the only neuromodulator with significantly extended duration
• You want a "naked" toxin without accessory proteins — Xeomin (incobotulinumtoxinA) is the only FDA-approved Type A product formulated without complexing proteins
• You are pregnant or breastfeeding — no botulinum toxin product is approved for use during pregnancy
• You have a known hypersensitivity to any botulinum toxin product or to cow's milk protein (Dysport contains lactose and may contain trace amounts of cow's milk protein)

Off-label use

Both Jeuveau and Dysport are FDA-approved specifically for the temporary improvement of moderate to severe glabellar lines (the vertical lines between the eyebrows). All other facial uses — forehead lines, crow's feet, masseter reduction, platysmal bands, "traptox," lip flip, and others — are off-label. Off-label use is common and legal when performed by a licensed provider exercising clinical judgment, but patients should be informed when a treatment is outside the labeled indication.

Safety profile

Both products carry the same class-level warnings that apply to all botulinum toxin products:

• Distant spread of toxin effect. In rare cases, botulinum toxin effects can spread beyond the injection site, causing generalized muscle weakness, ptosis, dysphagia, dysphonia, and breathing difficulties. These effects have been reported hours to weeks after injection. This risk is greatest in children treated for spasticity but applies to adults as well.
• Hypersensitivity reactions. Including anaphylaxis, have been reported. Immediate medical intervention should be available.
• Concurrent neuromuscular disorders. Patients with Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or myasthenia gravis may be at increased risk of serious adverse effects.
• No more frequent than every 3 months per labeled dosing for glabellar lines.

The most common adverse events for both products in clinical trials were localized: pain at injection site, headache, eyelid ptosis, and facial paresis. These are typically transient.

What to ask your provider

• Which neuromodulators do you carry, and why? A provider who only stocks one product cannot give you a neutral comparison.
• How do you decide which product to use for my anatomy? The answer should reference treatment area, muscle strength, your prior experience, and the product's spread profile — not just price.
• How many units will you use, and what is the per-unit cost? This lets you compare across products and providers on a meaningful basis.
• What happens if I do not like the result? Botulinum toxin effects are temporary, but a provider should have a plan for uneven results, ptosis, or other concerns at the 2-week follow-up.

Sources

• FDA. JEUVEAU (prabotulinumtoxinA-xvfs) Prescribing Information. BLA 761085. February 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s000lbl.pdf
• FDA. DYSPORT (abobotulinumtoxinA) Prescribing Information. BLA 125274. Updated labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125274s125lbl.pdf
• Beer KR, Shamban AT, Avelar RL, et al. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg. 2019;45(11):1381-1393. https://pmc.ncbi.nlm.nih.gov/articles/PMC6819028/
• FDA. JEUVEAU Approval Package, Application Number 761085Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761085Orig1s000Approv.pdf
• StatPearls. Botulinum Toxin Treatment of the Upper Face. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK574523/
• Aesthetic Training. FDA-Approved Botulinum Toxins for Aesthetic Use: Comparison. https://aesthetic-training.com/fda-approved-botulinum-toxins-for-aesthetic-use-comparison/